Clinical Trial Update: Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of bortezomib and docetaxel in patients with hormone-refractory prostate cancer; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Bortezomib (bortezomib)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: University of Southern California | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED